American pharmaceutical company Amgen announced its financial results for the second quarter ending June, with revenues reaching $8.39 billion, marking a 20% increase year-over-year and slightly exceeding market expectations of $8.37 billion. The growth in sales was primarily driven by established drugs such as Prolia for osteoporosis and Repatha for cholesterol reduction.

The company reported a net income of $746 million, a decrease of 46% compared to the same period last year. Adjusted earnings per share (EPS) came in at $4.97, narrowly missing the market consensus of $5.00.

Amgen has raised the lower end of its revenue guidance for the full year from $32.5 billion to $32.8 billion, while maintaining the upper limit at $33.8 billion. This is more optimistic than the market's expectation of $33.1 billion. The forecast for adjusted EPS is now projected to be within the range of $19.10 to $20.10, an upward adjustment from the previous guidance of $19.00 to $20.00, which also surpasses the market's estimate of $19.51.